Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Denosumab · Bildyos, Bilprevda

Monoclonal antibody · Antagonist of RANKL (TNFSF11) · developed by Amgen

Approved FDA, Jun 2010
AMGN Developer
1 Registered trials

What is Denosumab?

Denosumab is a fully human monoclonal antibody that binds RANKL and prevents its interaction with RANK receptor on osteoclasts, inhibiting osteoclast activity and bone resorption.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Bildyos, Bilprevda, Jubereq, Osvyrti, XGEVA, AMG-162
Drug type
Monoclonal antibody
Targets
RANKL (TNFSF11), RANK (TNFRSF11A) (binding partner it blocks)
Mechanism
Antagonist of RANKL (TNFSF11)
Pathways
osteoclast inhibition, bone resorption reduction
Therapy area
Oncology
Developer
Amgen (AMGN)
FDA status
Approved as Bildyos, Bilprevda, Jubereq (June 1, 2010), BLA125320 · FDA label
UNII
4EQZ6YO2HI

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 18, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02129699 Phase 3 Lung Cancer Non-small Cell Stage IV Terminated AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung Cancer Non-small Cell Stage IV

Other drugs acting on TNFSF11

AVT03 Phase 3

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Denosumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.